AKRO Akero Therapeutics, Inc. Insider Trading

CEO Cheng Andrew sold 30,000 shares of AKRO at $53.98; stock up 23.8% in 30 days, unprofitable company

Cheng Andrew, President and CEO, sold 30,000 shares (5.4% of pre-transaction holdings) at $53.98 on 2025-10-10, realizing $1,619,340.00 in proceeds. The sale occurred after a strong 23.8% 30-day rally and comes as the company reported negative net income of $-70,505,000.00 for its most recent full fiscal year. Within the same ticker, his four most recent sales (three on 2025-09-10 and one on 2025-09-11) have each generated 20.8%–25.3% post-sale gains within 30 days, though timing outcomes at the 90-day mark remain unmeasurable for all prior AKRO trades. His cross-ticker track record shows an average 90-day return of -0.2% following sells and a 61.54% well-timed rate, indicating mixed historical success at identifying inflection points before declines.

COO Young Jonathan sold 12,500 shares at blended average $47.76 on 2025-10-01, reducing holdings by 6.0%; stock now -19.9% from 52-week high.

Jonathan Young, Chief Operating Officer, executed 2 separate sales totaling 12,500 shares for $596,978.34 on 2025-10-01, leaving him with 196,898 shares post-transaction. The sale occurred near the 52-week high ($47.64 and $47.98 are close to the $57.56 peak), but the stock has since declined 19.9% to a current price of $46.10, suggesting the timing was favorable relative to subsequent price action. However, his cross-ticker track record shows prior open-market sells were poorly timed overall (90d average return +24.2% after sales, meaning the stock typically rose after he sold), and at AKRO specifically, the measurable same-ticker outcomes on prior sells have been mixed (30d returns ranging from -7.0% to +1.4%). The company remains unprofitable with net income of -$70,505,000.00, providing no fundamental tailwind to support the recent price decline. This sale reduces his stake by 6.0% and occurs in a stock environment where the long-term trend is downward despite a modest +1.0% 30-day bounce.

CEO Cheng Andrew sells 31,796 shares ($1.4M) across 4 transactions at $42.99–$44.62; stock down 24.5% from 52-week high.

Cheng Andrew, President and CEO of Akero Therapeutics, executed 4 separate sales totaling 31,796 shares (31.8K shares) for $1,374,665.15 ($1.4M) on September 10–11, 2025, at prices ranging from $42.99 to $44.62, reducing his holdings by 6.3% to 473,902 shares. The company remains unprofitable with a net loss of $70,505,000.00 over the most recent full fiscal year. Akero's stock has declined 24.5% from its 52-week high of $57.56 and is down 10.0% over the past 30 days, continuing a 21.9% decline over 90 days. The CEO's recent prior sales at this ticker on August 11 and July 10, 2025, have all shown negative returns: 30-day outcomes of -12.5%, -10.0%, -11.5%, -2.5%, and -0.2%, though 90-day outcomes on those earlier trades are not yet measurable.

Akero Therapeutics COO Jonathan Young sold 12,500 shares for $576,035.08 on 2025-09-02; stock down 23.5% from 52-week high and -11.2% over 30 days.

Jonathan Young, Chief Operating Officer of Akero Therapeutics, executed 3 separate sales totaling 12,500 shares for $576,035.08 at prices ranging from $45.78 to $47.58 on 2025-09-02, reducing his holdings by 6.0% to 197,484 shares. The transaction occurred as AKRO stock trades 23.5% below its 52-week high and has declined 11.2% over the past 30 days, suggesting sales into a weaker price environment. At the same ticker (AKRO), Young's prior 5 trades show mixed timing outcomes: his 2025-03-04 sales occurred before modest 90-day gains (+14.9%, +12.6%), while his 2025-02-03 sale preceded an 18-month-plus decline. The company reported negative net income of $70,505,000.00 for its most recent full fiscal year, indicating ongoing unprofitability. The divergence between the insider's cross-ticker track record (37.50% well-timed rate) and his AKRO-specific performance (20% well-timed rate on the 5 prior measurable sales) suggests limited predictive value of this individual's selling pattern at this stock.

COO Jonathan Young sold 12,500 AKRO shares for $597,325.95 on 2025-08-12 at blended avg $47.79

Jonathan Young, Chief Operating Officer of Akero Therapeutics, executed 2 separate sales totaling 12,500 shares (12.5K shares) for $597,325.95 at an average price of $47.79 on 2025-08-12, reducing his holdings by 6.0% to 197,484 shares (197.5K shares). The transaction occurred near the 52-week high—the current stock price of $48.31 is only 16.1% below the high of $57.56—but has declined 8.4% over the past 30 days despite a 90-day gain of 20.9%. Young's prior trade history at AKRO shows mixed timing outcomes: of his 5 prior sales at this ticker, only 2 were well-timed (the stock subsequently fell), while his cross-ticker track record across all tickers yields a 90-day well-timed rate of 37.50%, below the accuracy threshold that would indicate systematic skill. The company remains unprofitable with net income of -$70,505,000.00 ($-70.5M) over its most recent full fiscal year, adding fundamental context to the market environment in which this sale occurred.

CEO Cheng Andrew sold 30,000 shares (30.0K shares) for $1,457,595.98 in 3 separate transactions at AKRO on 2025-08-11; stock near 52-week lows.

Cheng Andrew, President and CEO, executed 3 separate sales totaling 30,000 shares (30.0K shares) for $1,457,595.98, reducing his holdings by 5.8% to 490,757 shares (490.8K shares). The sales occurred at prices between $48.07 and $49.44, while the stock currently trades at $48.31, down 16.1% from its 52-week high of $57.56 and down 8.4% over the past 30 days despite a 20.9% gain over the prior 90 days. The company is unprofitable with a net loss of $70,505,000.00 in its most recent full fiscal year. His same-ticker transaction history at AKRO shows 5 prior sells with mixed near-term results (30-day returns ranging from -0.2% to -4.3%), though longer-term timing outcomes remain unmeasurable. This large sale by the CEO during a period of stock weakness and amid operating losses warrants tracking to understand whether it reflects broader strategic reassessment or portfolio balancing by management.

CEO Andrew Cheng sells 30,000 AKRO shares for $1,534,894.87 across 2 transactions on 2025-07-10.

Andrew Cheng, President and CEO of Akero Therapeutics, executed 2 separate sales totaling 30,000 shares (30.0K shares) for $1,534,894.87 ($1.5M) at an average price of $51.16, reducing his holdings by 5.4% to 520,757 shares (520.8K shares). The current stock price of $51.57 is near the transaction prices and sits 10.4% below the 52-week high of $57.56, suggesting the sales occurred at a relative peak within the recent range. The company remains unprofitable with net income of $-70,725,000.00 ($-70.7M) over its most recent full fiscal year. Cheng's prior sales at AKRO have shown mixed near-term outcomes—three June sales declined 3.7% to 4.3% over 30 days, while two May sales rose 27.2% to 29.2% over 30 days—and his cross-ticker track record shows 20 prior sells with an average 90-day return of +4.6%, which indicates his sales have historically been poorly timed across his open-market trading history overall. The filing warrants review for context regarding the timing and volume of the sale relative to any company-specific developments.

AKRO CEO Cheng sold 37,837 shares at $54.05 avg for $2.0M; stock at 52-week highs near $57.56

Cheng Andrew, President and CEO, executed 3 separate sales totaling 37,837 shares for $2,044,939.67 at a blended average price of $54.05 on 2025-06-10, reducing his holdings by 6.4% to 556,487 shares. The sales occurred near the company's 52-week high of $57.56 (current price $53.56 is -7.0% from that peak), following a 33.9% surge over the prior 30 days and 21.3% gain over 90 days. Akero is unprofitable with net income of -$70,725,000 for the most recent full fiscal year. Across his cross-ticker track record of 20 prior sells, the insider's 90-day timing outcome has been mixed (70.59% well-timed rate), but at AKRO specifically, his 5 prior trades show 0 of 2 measurable 90-day sells were well-timed (both posted positive returns post-sale), suggesting his sales at this company have historically underperformed on timing.

CSO Rolph Timothy sells 37,500 AKRO shares for $2,044,633.55 (blended $54.52); 5 of 5 prior AKRO sells proved well-timed with negative 90-day returns.

Rolph Timothy, Chief Scientific Officer, executed 3 separate sales totaling 37,500 shares for $2,044,633.55 on June 5–6, 2025, reducing his holdings by 18.1% from 207,221 to 169,721 shares. This filing adds to a distinct pattern: all 5 of his prior trades at AKRO were sells, and each proved well-timed at the 90-day mark with negative returns ranging from -25.4% to -28.0%, meaning the stock declined after each prior sale. His cross-ticker track record shows an identical 100.00% well-timed rate on 8 prior sells. Against this backdrop, the company remains unprofitable (net income $-70,725,000.00 over the most recent full fiscal year), and the stock has risen 37.3% in the past 30 days and 24.8% in 90 days—positioning this sale near a 52-week high ($55.04 transaction price vs. $57.56 high). The consistency of well-timed sales at this ticker, combined with the recent sharp appreciation, suggests the insider perceived a tactical exit point.

CEO Andrew Cheng sold 30,000 shares ($1.2M) at $41.48 avg; stock at $40.01, down 30.5% from 52-week high

Cheng Andrew, President and CEO of Akero Therapeutics, executed 2 separate sales totaling 30,000 shares (30.0K shares) for $1,244,455.20 on 2025-05-12, reducing his holdings from 624,324 shares to 594,324 shares, a 4.8% decrease. The blended average sale price of $41.48 is modestly above the current market price of $40.01, placing the sales near recent trading levels. Akero reported a negative net income of $-70,725,000.00 for the most recent full fiscal year. His prior trades at this ticker show 2 of 2 measurable sales were well-timed at the 90-day mark (both followed by stock declines of -26.9% and -28.6%), and his cross-ticker track record across 20 prior sells demonstrates an 82.35% well-timed rate. The stock is currently down 19.1% over the past 90 days and down 30.5% from its 52-week high of $57.56.